866-997-4948(US-Canada Toll Free)

Metabolic Syndrome - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 75 Pages


Global Markets Directs, \'Metabolic Syndrome Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metabolic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metabolic Syndrome. Metabolic Syndrome Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metabolic Syndrome.
  • A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metabolic Syndrome pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metabolic Syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metabolic Syndrome Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Metabolic Syndrome 9
Metabolic Syndrome Therapeutics under Development by Companies 11
Metabolic Syndrome Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Metabolic Syndrome Therapeutics - Products under Development by Companies 18
Metabolic Syndrome Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Metabolic Syndrome Therapeutics Development 20
Dainippon Sumitomo Pharma Co., Ltd. 20
HYUNDAI PHARM. CO., LTD. 21
Chipscreen Biosciences Ltd 22
Jenrin Discovery, Inc. 23
Phenex Pharmaceuticals AG 24
Abeille Pharmaceuticals, Inc. 25
Cortendo Invest AB 26
Spherix Incorporated 27
Ache Laboratorios Farmaceuticos S/A 28
Cardax Pharmaceuticals, Inc. 29
Ascenion GmbH 30
Metabolic Syndrome - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AB-3001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MBX-8025 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CS-038 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
chloroquine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CDX-085 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Drug Targeting Farnesoid X Receptor - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SPX-10624258 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Px-102 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MB-12066 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HOB-046 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CDE-001 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GQ-16 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Next Generation Cortisol Inhibitor - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ACH-09 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ND-630 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MAS-G-Protein-Coupled Receptor Agonists - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KH-064 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
JD-5037 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Metabolic Syndrome Program - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Metabolic Syndrome SIRT Program - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ZLN-005 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Englerin A - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Metabolic Syndrome Program - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Drug Targeting Fibroblast Activation Protein - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Px-103 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Metabolic Syndrome Therapeutics - Drug Profile Updates 66
Metabolic Syndrome Therapeutics - Discontinued Products 68
Metabolic Syndrome Therapeutics - Dormant Products 69
Metabolic Syndrome - Product Development Milestones 70
Featured News & Press Releases 70
Aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound CDX-085 70
Apr 26, 2012: miRagen Announces Publication Of Data On MIRG-9103 In Journal Cell 70
Feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of KD025 71
Sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome 72
Jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome 72

Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Table


Number of Products Under Development for Metabolic Syndrome, H2 2013 9
Products under Development for Metabolic Syndrome - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 20
HYUNDAI PHARM. CO., LTD., H2 2013 21
Chipscreen Biosciences Ltd, H2 2013 22
Jenrin Discovery, Inc., H2 2013 23
Phenex Pharmaceuticals AG, H2 2013 24
Abeille Pharmaceuticals, Inc., H2 2013 25
Cortendo Invest AB, H2 2013 26
Spherix Incorporated, H2 2013 27
Ache Laboratorios Farmaceuticos S/A, H2 2013 28
Cardax Pharmaceuticals, Inc., H2 2013 29
Ascenion GmbH, H2 2013 30
Assessment by Monotherapy Products, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 35
Metabolic Syndrome Therapeutics - Drug Profile Updates 66
Metabolic Syndrome Therapeutics - Discontinued Products 68
Metabolic Syndrome Therapeutics - Dormant Products 69

List of Chart


Number of Products under Development for Metabolic Syndrome, H2 2013 9
Products under Development for Metabolic Syndrome - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 31
Assessment by Route of Administration, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Molecule Type, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *